Skip to main content
Top
Published in: Annals of Surgical Oncology 6/2016

Open Access 01-06-2016 | Head and Neck Oncology

Clinical Outcomes and Prognostic Factors for Salivary Duct Carcinoma: A Multi-Institutional Analysis of 141 Patients

Authors: Kuninori Otsuka, MD, Yorihisa Imanishi, MD, Yuichiro Tada, MD, Daisuke Kawakita, MD, Satoshi Kano, MD, Kiyoaki Tsukahara, MD, Akira Shimizu, MD, Hiroyuki Ozawa, MD, Kenji Okami, MD, Akihiro Sakai, MD, Yuichiro Sato, MD, Yushi Ueki, MD, Yukiko Sato, DDS, Toyoyuki Hanazawa, MD, Hideaki Chazono, MD, Kaoru Ogawa, MD, Toshitaka Nagao, MD

Published in: Annals of Surgical Oncology | Issue 6/2016

Login to get access

Abstract

Background

Among salivary gland malignancies, the prognosis of salivary duct carcinoma (SDC) is assumed to be the poorest. However, because of its low incidence, reliable survival estimates and prognostic factors based on a large number of patients remain to be elucidated, thereby making it impossible to standardize the optimal treatment for SDC.

Methods

We performed this multi-institutional, retrospective analysis by collecting the clinical information of 141 patients with SDC without distant metastasis who underwent curative surgery as the initial treatment to elucidate overall survival (OS) and disease-free survival (DFS) along with their prognostic factors.

Results

The 3-year OS and DFS rates were 70.5 and 38.2 %, respectively. Multivariate analysis revealed that age ≥65 years (p < 0.001) and N1 and N2 (p = 0.047 and <0.001, respectively) were independent prognostic factors for OS, whereas the primary site of the minor salivary and sublingual gland (p < 0.001) and N2 (p < 0.001) were those for DFS. The most common treatment failure was distant metastasis (55 patients, 39.0 %). For early parotid SDC, neither total parotidectomy in the patients with early T stage nor nerve resection in the patients without facial nerve palsy showed survival benefits.

Conclusions

Advanced N stage independently affects both OS and DFS. Partial parotidectomy with facial nerve preservation could be a less invasive standard surgical procedure for parotid gland SDC in the early T stage without facial nerve palsy. Effective systemic therapy is imperative to improve DFS of SDC.
Literature
1.
go back to reference Barnes L, Eveson JW, Reichart P, Sidaransky D, eds. World Health Organization classification of tumours. Pathology and genetics of head and neck tumours. Lyon: IARC Press; 2005. Barnes L, Eveson JW, Reichart P, Sidaransky D, eds. World Health Organization classification of tumours. Pathology and genetics of head and neck tumours. Lyon: IARC Press; 2005.
2.
go back to reference McHugh JB, Visscher DW, Barnes EL. Update on selected salivary gland neoplasms. Arch Pathol Lab Med. 2009;133:1763–74.PubMed McHugh JB, Visscher DW, Barnes EL. Update on selected salivary gland neoplasms. Arch Pathol Lab Med. 2009;133:1763–74.PubMed
3.
go back to reference Kleinsasser O, Klein HJ, Hubner G. Salivary duct carcinoma. A group of salivary gland tumors analogous to mammary duct carcinoma. Arch Klin Exp Ohren Nasen Kehlkopfheilkd. 1968;192:100–5.CrossRefPubMed Kleinsasser O, Klein HJ, Hubner G. Salivary duct carcinoma. A group of salivary gland tumors analogous to mammary duct carcinoma. Arch Klin Exp Ohren Nasen Kehlkopfheilkd. 1968;192:100–5.CrossRefPubMed
4.
go back to reference Seifert G, Brocheriou C, Cardesa A, Eveson JW. WHO International histological classification of tumours. Tentative histological classification of salivary gland tumours. Pathol Res Pract. 1990;186:555–81.CrossRefPubMed Seifert G, Brocheriou C, Cardesa A, Eveson JW. WHO International histological classification of tumours. Tentative histological classification of salivary gland tumours. Pathol Res Pract. 1990;186:555–81.CrossRefPubMed
5.
go back to reference Etges A, Pinto DS, Jr., Kowalski LP, Soares FA, Araujo VC. Salivary duct carcinoma: immunohistochemical profile of an aggressive salivary gland tumour. J Clin Pathol. 2003;56:914–8.CrossRefPubMedPubMedCentral Etges A, Pinto DS, Jr., Kowalski LP, Soares FA, Araujo VC. Salivary duct carcinoma: immunohistochemical profile of an aggressive salivary gland tumour. J Clin Pathol. 2003;56:914–8.CrossRefPubMedPubMedCentral
6.
go back to reference Hosal AS, Fan C, Barnes L, Myers EN. Salivary duct carcinoma. Otolaryngol Head Neck Surg. 2003;129:720–5.CrossRefPubMed Hosal AS, Fan C, Barnes L, Myers EN. Salivary duct carcinoma. Otolaryngol Head Neck Surg. 2003;129:720–5.CrossRefPubMed
7.
go back to reference Barnes L, Rao U, Krause J, Contis L, Schwartz A, Scalamogna P. Salivary duct carcinoma. Part I. A clinicopathologic evaluation and DNA image analysis of 13 cases with review of the literature. Oral Surg Oral Med Oral Pathol. 1994;78:64-73.CrossRefPubMed Barnes L, Rao U, Krause J, Contis L, Schwartz A, Scalamogna P. Salivary duct carcinoma. Part I. A clinicopathologic evaluation and DNA image analysis of 13 cases with review of the literature. Oral Surg Oral Med Oral Pathol. 1994;78:64-73.CrossRefPubMed
8.
go back to reference Guzzo M, Di Palma S, Grandi C, Molinari R. Salivary duct carcinoma: clinical characteristics and treatment strategies. Head Neck. 1997;19:126–33.CrossRefPubMed Guzzo M, Di Palma S, Grandi C, Molinari R. Salivary duct carcinoma: clinical characteristics and treatment strategies. Head Neck. 1997;19:126–33.CrossRefPubMed
9.
10.
go back to reference Lewis JE, McKinney BC, Weiland LH, Ferreiro JA, Olsen KD. Salivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases. Cancer. 1996;77:223–30.CrossRefPubMed Lewis JE, McKinney BC, Weiland LH, Ferreiro JA, Olsen KD. Salivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases. Cancer. 1996;77:223–30.CrossRefPubMed
11.
go back to reference Jaehne M, Roeser K, Jaekel T, Schepers JD, Albert N, Loning T. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer. 2005;103:2526–33.CrossRefPubMed Jaehne M, Roeser K, Jaekel T, Schepers JD, Albert N, Loning T. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer. 2005;103:2526–33.CrossRefPubMed
12.
go back to reference Roh JL, Lee JI, Choi SH, et al. Prognostic factors and oncologic outcomes of 56 salivary duct carcinoma patients in a single institution: high rate of systemic failure warrants targeted therapy. Oral Oncol. 2014;50:e64–6.CrossRefPubMed Roh JL, Lee JI, Choi SH, et al. Prognostic factors and oncologic outcomes of 56 salivary duct carcinoma patients in a single institution: high rate of systemic failure warrants targeted therapy. Oral Oncol. 2014;50:e64–6.CrossRefPubMed
14.
go back to reference Jayaprakash V, Merzianu M, Warren GW, et al. Survival rates and prognostic factors for infiltrating salivary duct carcinoma: analysis of 228 cases from the Surveillance, Epidemiology, and End Results database. Head Neck. 2014;36:694–701.CrossRefPubMedPubMedCentral Jayaprakash V, Merzianu M, Warren GW, et al. Survival rates and prognostic factors for infiltrating salivary duct carcinoma: analysis of 228 cases from the Surveillance, Epidemiology, and End Results database. Head Neck. 2014;36:694–701.CrossRefPubMedPubMedCentral
15.
go back to reference AJCC cancer staging manual. 7th ed. New York: Springer; 2010. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
16.
go back to reference Williams MD, Roberts D, Blumenschein GR Jr., et al. Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients. Am J Surg Pathol. 2007;31:1645–52.CrossRefPubMed Williams MD, Roberts D, Blumenschein GR Jr., et al. Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients. Am J Surg Pathol. 2007;31:1645–52.CrossRefPubMed
17.
go back to reference Kim JY, Lee S, Cho KJ, et al. Treatment results of post-operative radiotherapy in patients with salivary duct carcinoma of the major salivary glands. Br J Radiol. 2012;85:e947–52.CrossRefPubMedPubMedCentral Kim JY, Lee S, Cho KJ, et al. Treatment results of post-operative radiotherapy in patients with salivary duct carcinoma of the major salivary glands. Br J Radiol. 2012;85:e947–52.CrossRefPubMedPubMedCentral
18.
go back to reference Felix A, El-Naggar AK, Press MF, et al. Prognostic significance of biomarkers (c-erbB-2, p53, proliferating cell nuclear antigen, and DNA content) in salivary duct carcinoma. Hum Pathol. 1996;27:561–6.CrossRefPubMed Felix A, El-Naggar AK, Press MF, et al. Prognostic significance of biomarkers (c-erbB-2, p53, proliferating cell nuclear antigen, and DNA content) in salivary duct carcinoma. Hum Pathol. 1996;27:561–6.CrossRefPubMed
19.
go back to reference Surakanti SG, Agulnik M. Salivary gland malignancies: the role for chemotherapy and molecular targeted agents. Semin Oncol. 2008;35:309–19.CrossRefPubMed Surakanti SG, Agulnik M. Salivary gland malignancies: the role for chemotherapy and molecular targeted agents. Semin Oncol. 2008;35:309–19.CrossRefPubMed
20.
go back to reference Kapadia SB, Barnes L. Expression of androgen receptor, gross cystic disease fluid protein, and CD44 in salivary duct carcinoma. Mod Pathol. 1998;11:1033–8.PubMed Kapadia SB, Barnes L. Expression of androgen receptor, gross cystic disease fluid protein, and CD44 in salivary duct carcinoma. Mod Pathol. 1998;11:1033–8.PubMed
21.
go back to reference Fan CY, Wang J, Barnes EL. Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature. Am J Surg Pathol. 2000;24:579–86.CrossRefPubMed Fan CY, Wang J, Barnes EL. Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature. Am J Surg Pathol. 2000;24:579–86.CrossRefPubMed
22.
go back to reference Hoang MP, Callender DL, Sola Gallego JJ, et al. Molecular and biomarker analyses of salivary duct carcinomas: comparison with mammary duct carcinoma. Int J Oncol. 2001;19:865–71.PubMed Hoang MP, Callender DL, Sola Gallego JJ, et al. Molecular and biomarker analyses of salivary duct carcinomas: comparison with mammary duct carcinoma. Int J Oncol. 2001;19:865–71.PubMed
23.
go back to reference Kay PA, Roche PC, Olsen KD. Salivary duct carcinoma: immunohistochemical analysis of androgen receptor, prostate markers and HER-2/neu oncoprotein in 40 cases [abstract]. Mod Pathol. 2001;14:150A.CrossRef Kay PA, Roche PC, Olsen KD. Salivary duct carcinoma: immunohistochemical analysis of androgen receptor, prostate markers and HER-2/neu oncoprotein in 40 cases [abstract]. Mod Pathol. 2001;14:150A.CrossRef
24.
go back to reference Locati LD, Perrone F, Losa M, et al. Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs). Oral Oncol. 2009;45:986–90.CrossRefPubMed Locati LD, Perrone F, Losa M, et al. Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs). Oral Oncol. 2009;45:986–90.CrossRefPubMed
25.
go back to reference Skalova A, Starek I, Vanecek T, et al. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in situ hybridization and immunohistochemistry. Histopathology. 2003;42:348–56.CrossRefPubMed Skalova A, Starek I, Vanecek T, et al. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in situ hybridization and immunohistochemistry. Histopathology. 2003;42:348–56.CrossRefPubMed
26.
go back to reference Cornolti G, Ungari M, Morassi ML, et al. Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland. Arch Otolaryngol Head Neck Surg. 2007;133:1031–6.CrossRefPubMed Cornolti G, Ungari M, Morassi ML, et al. Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland. Arch Otolaryngol Head Neck Surg. 2007;133:1031–6.CrossRefPubMed
27.
go back to reference Williams MD, Roberts DB, Kies MS, Mao L, Weber RS, El-Naggar AK. Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance. Clin Cancer Res. 2010;16:2266–74.CrossRefPubMedPubMedCentral Williams MD, Roberts DB, Kies MS, Mao L, Weber RS, El-Naggar AK. Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance. Clin Cancer Res. 2010;16:2266–74.CrossRefPubMedPubMedCentral
28.
go back to reference Jaspers HC, Verbist BM, Schoffelen R, et al. Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options. J Clin Oncol. 2011;29:e473–6.CrossRefPubMed Jaspers HC, Verbist BM, Schoffelen R, et al. Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options. J Clin Oncol. 2011;29:e473–6.CrossRefPubMed
29.
go back to reference Krishnamurthy J, Krishnamurty DM, Baker JJ, Zhen W, Lydiatt D, Ganti AK. Salivary duct carcinoma responding to trastuzumab-based therapy: case report and review of the literature. Head Neck. 2013;35:E372–5.CrossRefPubMed Krishnamurthy J, Krishnamurty DM, Baker JJ, Zhen W, Lydiatt D, Ganti AK. Salivary duct carcinoma responding to trastuzumab-based therapy: case report and review of the literature. Head Neck. 2013;35:E372–5.CrossRefPubMed
31.
go back to reference Locati LD, Perrone F, Cortelazzi B, et al. Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers. Head Neck. 2014. doi:10.1002/hed.23940. Locati LD, Perrone F, Cortelazzi B, et al. Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers. Head Neck. 2014. doi:10.​1002/​hed.​23940.
32.
go back to reference Guntinas-Lichius O, Klussmann JP, Schroeder U, Quante G, Jungehuelsing M, Stennert E. Primary parotid malignoma surgery in patients with normal preoperative facial nerve function: outcome and long-term postoperative facial nerve function. Laryngoscope. 2004;114:949–56.CrossRefPubMed Guntinas-Lichius O, Klussmann JP, Schroeder U, Quante G, Jungehuelsing M, Stennert E. Primary parotid malignoma surgery in patients with normal preoperative facial nerve function: outcome and long-term postoperative facial nerve function. Laryngoscope. 2004;114:949–56.CrossRefPubMed
33.
go back to reference Vander Poorten V, Bradley PJ, Takes RP, Rinaldo A, Woolgar JA, Ferlito A. Diagnosis and management of parotid carcinoma with a special focus on recent advances in molecular biology. Head Neck. 2012;34:429–40.CrossRef Vander Poorten V, Bradley PJ, Takes RP, Rinaldo A, Woolgar JA, Ferlito A. Diagnosis and management of parotid carcinoma with a special focus on recent advances in molecular biology. Head Neck. 2012;34:429–40.CrossRef
Metadata
Title
Clinical Outcomes and Prognostic Factors for Salivary Duct Carcinoma: A Multi-Institutional Analysis of 141 Patients
Authors
Kuninori Otsuka, MD
Yorihisa Imanishi, MD
Yuichiro Tada, MD
Daisuke Kawakita, MD
Satoshi Kano, MD
Kiyoaki Tsukahara, MD
Akira Shimizu, MD
Hiroyuki Ozawa, MD
Kenji Okami, MD
Akihiro Sakai, MD
Yuichiro Sato, MD
Yushi Ueki, MD
Yukiko Sato, DDS
Toyoyuki Hanazawa, MD
Hideaki Chazono, MD
Kaoru Ogawa, MD
Toshitaka Nagao, MD
Publication date
01-06-2016
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 6/2016
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-015-5082-2

Other articles of this Issue 6/2016

Annals of Surgical Oncology 6/2016 Go to the issue